Pay in 4 interest-free payments of $6.58 Learn more
Ships within 48 hours · Estimated delivery Aug 21 - Aug 26
Nevertheless, the trial-specific modified device demonstrated insufficient reliability in a clinical study, necessitating its mid-trial replacement with the Precision Olfactory Delivery (POD) device (Impel Pharmaceuticals, Seattle, WA) [67]
A phase IIa active-comparator-controlled study to evaluate the efficacy and safety of efinopegdutide in patients with non-alcoholic fatty liver disease
Each vial contains0.9% benzyl alcohol, a preservative that inhibits bacterial growth, ensuringsafe multi-dose use
These methods can help sustain adequate B12 levels and are often more convenient for long-term use
2020;19(6):e13124
US$ 23.93
US$ 22.67
US$ 29.04
US$ 26.49
